Regeneron’s Linvoseltamab CRL Underlines Risks Of Third-Party Manufacturers

 
• By Bridget Silverman

The bispecific antibody is the latest example of a growing number of biologics receiving complete response letters related to third-party manufacturing facilities.

fermentation
Several CRLs have been issued recently because of third-party manufacturer issues. • Source: Shutterstock

More from Manufacturing

More from Compliance